Jim Greenwood, BIO
October 8, 2019 12:02 PM EDT
People

Jim Green­wood set to de­part from BIO af­ter US elec­tions — vows to en­sure law­mak­ers don't 'kill in­no­va­tion'

Natalie Grover

Reporter

The her­culean US drug lob­by is los­ing one of its flag­bear­ers: BIO CEO Jim Green­wood.

For more than 14 years Green­wood has led BIO, which …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times